A multi-institutional review of outcomes of endometrial stromal sarcoma

Charles A. Leath, Warner K. Huh, Johnny Hyde, David E. Cohn, Kimberly E. Resnick, Nicholas P. Taylor, Matthew A. Powell, David G. Mutch, William H. Bradley, Melissa A. Geller, Peter A. Argenta, Michael A. Gold

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Objective.: To compare the clinical behavior and outcomes of low- and high-grade endometrial stromal sarcomas (LGESS and HGESS), respectively. Methods.: Patients with endometrial stromal sarcoma from five different institutions were identified and reviewed for clinicopathologic variables, surgical management and outcomes. Statistical calculations including Chi-square, t-test and survival using the Kaplan-Meier method with the log rank test were performed. Results.: One hundred and five patients were identified with 72 having LGESS, 31 with HGESS and 2 having unclassified tumors. The mean age was 50 years for patients with LGESS and 64 years for those with HGESS (p < 0.0001). In patients with LGESS, 68% (49 patients) had disease confined to the uterine corpus or cervix compared to 39% (12 patients) in HGESS (p = 0.002). The median overall survival was 53 months for HGESS and had not yet been reached in LGESS with 87.8% alive at 80 months (p < 0.0001). In HGESS patients with extrauterine disease, the presence of residual disease greater than 2 cm had a significant effect on median survival. Median survival was 52 months for those who underwent optimal cytoreduction versus 2 months for those with suboptimal residual disease (p = 0.007). The impact of cytoreduction was not seen in LGESS patients with extrauterine disease with 82.1% alive at 78 months. Conclusions.: Low-grade and high-grade endometrial stromal sarcomas represent two distinct clinical entities and should be treated as such. Survival in patients with high-grade tumors appears to be related to amount of residual disease at the completion of initial surgery and would suggest the need for aggressive cytoreduction. The role of surgical staging and optimal adjuvant therapy remains unclear.

Original languageEnglish (US)
Pages (from-to)630-634
Number of pages5
JournalGynecologic oncology
Volume105
Issue number3
DOIs
StatePublished - Jun 1 2007

Fingerprint

Endometrial Stromal Sarcoma
Survival
Chi-Square Distribution
Cervix Uteri
Neoplasms

Keywords

  • Endometrial stromal sarcoma
  • High-grade endometrial stromal sarcoma
  • Low-grade endometrial stromal sarcoma
  • Multi-institutional study
  • Outcomes

Cite this

Leath, C. A., Huh, W. K., Hyde, J., Cohn, D. E., Resnick, K. E., Taylor, N. P., ... Gold, M. A. (2007). A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecologic oncology, 105(3), 630-634. https://doi.org/10.1016/j.ygyno.2007.01.031

A multi-institutional review of outcomes of endometrial stromal sarcoma. / Leath, Charles A.; Huh, Warner K.; Hyde, Johnny; Cohn, David E.; Resnick, Kimberly E.; Taylor, Nicholas P.; Powell, Matthew A.; Mutch, David G.; Bradley, William H.; Geller, Melissa A.; Argenta, Peter A.; Gold, Michael A.

In: Gynecologic oncology, Vol. 105, No. 3, 01.06.2007, p. 630-634.

Research output: Contribution to journalArticle

Leath, CA, Huh, WK, Hyde, J, Cohn, DE, Resnick, KE, Taylor, NP, Powell, MA, Mutch, DG, Bradley, WH, Geller, MA, Argenta, PA & Gold, MA 2007, 'A multi-institutional review of outcomes of endometrial stromal sarcoma', Gynecologic oncology, vol. 105, no. 3, pp. 630-634. https://doi.org/10.1016/j.ygyno.2007.01.031
Leath CA, Huh WK, Hyde J, Cohn DE, Resnick KE, Taylor NP et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecologic oncology. 2007 Jun 1;105(3):630-634. https://doi.org/10.1016/j.ygyno.2007.01.031
Leath, Charles A. ; Huh, Warner K. ; Hyde, Johnny ; Cohn, David E. ; Resnick, Kimberly E. ; Taylor, Nicholas P. ; Powell, Matthew A. ; Mutch, David G. ; Bradley, William H. ; Geller, Melissa A. ; Argenta, Peter A. ; Gold, Michael A. / A multi-institutional review of outcomes of endometrial stromal sarcoma. In: Gynecologic oncology. 2007 ; Vol. 105, No. 3. pp. 630-634.
@article{401f73ef4fb6494bbb3ab4d56f8ed7b9,
title = "A multi-institutional review of outcomes of endometrial stromal sarcoma",
abstract = "Objective.: To compare the clinical behavior and outcomes of low- and high-grade endometrial stromal sarcomas (LGESS and HGESS), respectively. Methods.: Patients with endometrial stromal sarcoma from five different institutions were identified and reviewed for clinicopathologic variables, surgical management and outcomes. Statistical calculations including Chi-square, t-test and survival using the Kaplan-Meier method with the log rank test were performed. Results.: One hundred and five patients were identified with 72 having LGESS, 31 with HGESS and 2 having unclassified tumors. The mean age was 50 years for patients with LGESS and 64 years for those with HGESS (p < 0.0001). In patients with LGESS, 68{\%} (49 patients) had disease confined to the uterine corpus or cervix compared to 39{\%} (12 patients) in HGESS (p = 0.002). The median overall survival was 53 months for HGESS and had not yet been reached in LGESS with 87.8{\%} alive at 80 months (p < 0.0001). In HGESS patients with extrauterine disease, the presence of residual disease greater than 2 cm had a significant effect on median survival. Median survival was 52 months for those who underwent optimal cytoreduction versus 2 months for those with suboptimal residual disease (p = 0.007). The impact of cytoreduction was not seen in LGESS patients with extrauterine disease with 82.1{\%} alive at 78 months. Conclusions.: Low-grade and high-grade endometrial stromal sarcomas represent two distinct clinical entities and should be treated as such. Survival in patients with high-grade tumors appears to be related to amount of residual disease at the completion of initial surgery and would suggest the need for aggressive cytoreduction. The role of surgical staging and optimal adjuvant therapy remains unclear.",
keywords = "Endometrial stromal sarcoma, High-grade endometrial stromal sarcoma, Low-grade endometrial stromal sarcoma, Multi-institutional study, Outcomes",
author = "Leath, {Charles A.} and Huh, {Warner K.} and Johnny Hyde and Cohn, {David E.} and Resnick, {Kimberly E.} and Taylor, {Nicholas P.} and Powell, {Matthew A.} and Mutch, {David G.} and Bradley, {William H.} and Geller, {Melissa A.} and Argenta, {Peter A.} and Gold, {Michael A.}",
year = "2007",
month = "6",
day = "1",
doi = "10.1016/j.ygyno.2007.01.031",
language = "English (US)",
volume = "105",
pages = "630--634",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A multi-institutional review of outcomes of endometrial stromal sarcoma

AU - Leath, Charles A.

AU - Huh, Warner K.

AU - Hyde, Johnny

AU - Cohn, David E.

AU - Resnick, Kimberly E.

AU - Taylor, Nicholas P.

AU - Powell, Matthew A.

AU - Mutch, David G.

AU - Bradley, William H.

AU - Geller, Melissa A.

AU - Argenta, Peter A.

AU - Gold, Michael A.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Objective.: To compare the clinical behavior and outcomes of low- and high-grade endometrial stromal sarcomas (LGESS and HGESS), respectively. Methods.: Patients with endometrial stromal sarcoma from five different institutions were identified and reviewed for clinicopathologic variables, surgical management and outcomes. Statistical calculations including Chi-square, t-test and survival using the Kaplan-Meier method with the log rank test were performed. Results.: One hundred and five patients were identified with 72 having LGESS, 31 with HGESS and 2 having unclassified tumors. The mean age was 50 years for patients with LGESS and 64 years for those with HGESS (p < 0.0001). In patients with LGESS, 68% (49 patients) had disease confined to the uterine corpus or cervix compared to 39% (12 patients) in HGESS (p = 0.002). The median overall survival was 53 months for HGESS and had not yet been reached in LGESS with 87.8% alive at 80 months (p < 0.0001). In HGESS patients with extrauterine disease, the presence of residual disease greater than 2 cm had a significant effect on median survival. Median survival was 52 months for those who underwent optimal cytoreduction versus 2 months for those with suboptimal residual disease (p = 0.007). The impact of cytoreduction was not seen in LGESS patients with extrauterine disease with 82.1% alive at 78 months. Conclusions.: Low-grade and high-grade endometrial stromal sarcomas represent two distinct clinical entities and should be treated as such. Survival in patients with high-grade tumors appears to be related to amount of residual disease at the completion of initial surgery and would suggest the need for aggressive cytoreduction. The role of surgical staging and optimal adjuvant therapy remains unclear.

AB - Objective.: To compare the clinical behavior and outcomes of low- and high-grade endometrial stromal sarcomas (LGESS and HGESS), respectively. Methods.: Patients with endometrial stromal sarcoma from five different institutions were identified and reviewed for clinicopathologic variables, surgical management and outcomes. Statistical calculations including Chi-square, t-test and survival using the Kaplan-Meier method with the log rank test were performed. Results.: One hundred and five patients were identified with 72 having LGESS, 31 with HGESS and 2 having unclassified tumors. The mean age was 50 years for patients with LGESS and 64 years for those with HGESS (p < 0.0001). In patients with LGESS, 68% (49 patients) had disease confined to the uterine corpus or cervix compared to 39% (12 patients) in HGESS (p = 0.002). The median overall survival was 53 months for HGESS and had not yet been reached in LGESS with 87.8% alive at 80 months (p < 0.0001). In HGESS patients with extrauterine disease, the presence of residual disease greater than 2 cm had a significant effect on median survival. Median survival was 52 months for those who underwent optimal cytoreduction versus 2 months for those with suboptimal residual disease (p = 0.007). The impact of cytoreduction was not seen in LGESS patients with extrauterine disease with 82.1% alive at 78 months. Conclusions.: Low-grade and high-grade endometrial stromal sarcomas represent two distinct clinical entities and should be treated as such. Survival in patients with high-grade tumors appears to be related to amount of residual disease at the completion of initial surgery and would suggest the need for aggressive cytoreduction. The role of surgical staging and optimal adjuvant therapy remains unclear.

KW - Endometrial stromal sarcoma

KW - High-grade endometrial stromal sarcoma

KW - Low-grade endometrial stromal sarcoma

KW - Multi-institutional study

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=34248386886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248386886&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2007.01.031

DO - 10.1016/j.ygyno.2007.01.031

M3 - Article

C2 - 17320937

AN - SCOPUS:34248386886

VL - 105

SP - 630

EP - 634

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -